Nanoparticles as potential clinical therapeutic agents in Alzheimer's disease: focus on selenium nanoparticles
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, cilt.10, sa.7, ss.773-782, 2017 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 10 Sayı: 7
- Basım Tarihi: 2017
- Doi Numarası: 10.1080/17512433.2017.1324781
- Dergi Adı: EXPERT REVIEW OF CLINICAL PHARMACOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.773-782
- Süleyman Demirel Üniversitesi Adresli: Evet
Özet
Introduction: In etiology of Alzheimer's disease (AD), involvement of amyloid (A) plaque accumulation and oxidative stress in the brain have important roles. Several nanoparticles such as titanium dioxide, silica dioxide, silver and zinc oxide have been experimentally using for treatment of neurological disease. In the last decade, there has been a great interest on combination of antioxidant bioactive compounds such as selenium (Se) and flavonoids with the oxidant nanoparticles in AD. We evaluated the most current data available on the physiological effects of oxidant and antioxidant nanoparticles.